Biogen Idec Inc. (BIIB), Celgene Corporation (CELG), Gilead Sciences, Inc. (GILD): 3 of Biotech’s Best

Page 1 of 2

It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market. Industry companies have thrived thanks to technological advances that facilitated new discoveries and stoked greater demand for life-enhancing and lifesaving products.

Industry research firm IBIS World estimates global biotechnology industry revenue will jump 12.7% in 2013, reaching $262 billion. That follows an average annual growth rate of 11% over the last five years.

Moreover, the industry is still in the growth stage of its life cycle. Constant technological findings, an insatiable appetite for new and better drugs, and the explosive growth of emerging markets will influence and fuel the industry. Let’s take a closer look at three of biotech’s best.

One of the biggest

Biogen Idec Inc (NASDAQ:BIIB)

Biogen Idec Inc. (NASDAQ:BIIB), one of the biggest and best-known names in the biotech sector, is up some 40% since the start of 2013, and a whopping 120% over the past two years.

Driving the Massachusetts based company is a solid pipeline of drugs to treat multiple sclerosis. The firm also has a number of other therapies to treat diseases such as rheumatoid arthritis, lymphomas, Crohn’s disease, and psoriasis.

Tecfidera is Biogen Idec Inc. (NASDAQ:BIIB)’s new oral therapy recently approved in the U.S. for the treatment of relapsing forms of MS. The drug has been proven to significantly reduce important measures of the disease, including relapses and the development of brain lesions.

In addition, it is shown to slow disability progression over time.  Only on the market for a few months, Tecfidera sales have already surpassed even the loftiest expectations and are on pace to reach $800 million this year.

Biogen Idec Inc. (NASDAQ:BIIB)’s 2013 full year earnings are expected to grow 21.4%, with several analysts becoming more upbeat over the last few weeks. Consensus for this year’s cumulative earnings have risen to $7.66. Meanwhile, full 2014 consensus numbers have surged from $8.77 to $10.17.  Founded in 1978, Biogen Idec Inc. (NASDAQ:BIIB) is the world’s oldest independent biotechnology company and boasts more than $5 billion in annual revenue

The innovator

Celgene Corporation (NASDAQ:CELG), a global biopharmaceutical company with a market cap of $51 billion, is on a mission to deliver truly innovative and life changing drugs. There are more than 300 clinical trials at major medical centers using compounds from Celgene Corporation (NASDAQ:CELG) for the treatment of myriad cancers and rare blood diseases.

Shares have been on a tear, doubling over the last 12 months. Yet that hasn’t stopped a handful of analysts from further upgrading shares even at today’s levels.

Recently, Jefferies Group reaffirmed its “buy” rating and has a $152 price target. Cantor Fitzgerald and Guggenheim both reiterated “buy” ratings and $142 price targets. And, Argus raised its guidance from  to “buy” from “hold” and have a $140 price target on the stock.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!